Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Sigyn Therapeutics is a tiny early-stage biotech trying to build blood-cleansing devices that filter harmful stuff out of a patient's bloodstream.
Sigyn Therapeutics is a tiny, pre-revenue biotech company based in San Diego, California. It does not sell anything yet, and it has no product approved by regulators. Instead, it is a research-stage company working on machines and cartridges that clean a patient's blood outside the body, a process called therapeutic apheresis. Think of it like a dialysis machine for the bloodstream, except instead of removing waste that kidneys normally handle, Sigyn wants to pull out things like cancer-related proteins, inflammatory molecules, and dangerous toxins that make people sick or weaken their immune system. The company's main programs are a blood pump device called the ImmunePrep cartridge system and a related machine it calls the "Sigyn Therapeutics Device."
Because Sigyn has no sales, no profits, and no approved products, it survives by raising money from investors, mostly through selling stock on the OTCQB market. Its market value sits around a few million dollars, which is tiny even by small-cap standards. The company funds its research and early testing with that cash, and its biggest challenge is simply staying alive long enough to prove its technology works in humans. The business only becomes real if one of its blood-cleansing ideas passes clinical trials, wins regulatory clearance, and gets hospitals or clinics to buy it. Until then, shareholders are betting on a science experiment, not a business with customers.
The company was founded by James Joyce, who has led several small medical device ventures, and it has spent recent years announcing early collaborations and preclinical work while burning through limited cash. Research-stage biotechs like this often dilute shareholders heavily to survive, since there is no revenue to reinvest and no free cash flow to speak of. For a curious reader, the key takeaway is this: Sigyn is not a company you analyze like a normal business with margins and growth. It is a lottery ticket on a medical idea, and the most important things to watch are whether it raises more money, whether its blood-filtering technology shows real results, and whether regulators ever let it near actual patients.
Saved answer · last researched 11 Oct 2026